Harmony Biosciences
HRMY
221 hedge funds and large institutions have $1.58B invested in Harmony Biosciences in 2023 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 62 increasing their positions, 77 reducing their positions, and 35 closing their positions.
215% more call options, than puts
Call options by funds: $5.6M | Put options by funds: $1.78M
57% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 35
8% more funds holding
Funds holding: 204 → 221 (+17)
1.31% more ownership
Funds ownership: 82.38% → 83.69% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less capital invested
Capital invested by funds: $1.62B → $1.58B (-$43M)
19% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 77
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$39.6M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$34.2M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$20.9M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$14M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$6.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$36.8M |
| 2 |
PA
Perceptive Advisors
New York
|
-$32.6M |
| 3 |
NPIC
Neumeier Poma Investment Counsel
Carmel,
California
|
-$19.5M |
| 4 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
-$14.2M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$10.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
251
Creative Planning
Overland Park,
Kansas
| – | -$2.42K | -74 | Closed |
|
|
MPWT
252
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| – | -$2.33K | -71 | Closed |
|
|
GA
253
GoalVest Advisory
New York
| – | -$2.23K | -68 | Closed |
|
|
NFSG
254
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$950 | -29 | Closed |
|
|
IA
255
IFP Advisors
Tampa,
Florida
| – | -$819 | -25 | Closed |
|
|
FLC
256
Fifth Lane Capital
Austin,
Texas
| – | +$2.79M | +100,000 | New |
|
HRMY Hedge Fund Activity: Q4 2023 in Review
221 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q4 2023, worth a combined $1.58B — down 2.7% from $1.62B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new HRMY positions and 35 closed out — a net gain of 20 holders — while 62 added to existing stakes and 77 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $39.6M. The largest seller was Adage Capital Partners, cutting an estimated $36.8M.
- 221 institutional investors held Harmony Biosciences (HRMY) as of Q4 2023, up from 204 in Q3 2023.
- Funds reported $1.58B of Harmony Biosciences stock for Q4 2023, down 2.7% quarter-over-quarter.
- 55 funds opened new Harmony Biosciences positions in Q4 2023 and 35 closed out, a net change of +20 holders.
- The largest Harmony Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $39.6M added.
- The largest Harmony Biosciences seller in Q4 2023 was Adage Capital Partners, an estimated $36.8M sold.
Based on aggregated 13F filings for Q4 2023.